JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Apellis Pharmaceuticals Inc

Închisă

SectorSănătate

28.6 1.89

Rezumat

Modificarea prețului

24h

Curent

Minim

28.02

Maxim

28.89

Indicatori cheie

By Trading Economics

Venit

50M

-42M

Vânzări

12M

178M

Marjă de profit

-23.615

Angajați

705

EBITDA

50M

-30M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+28.14% upside

Dividende

By Dow Jones

Următoarele câștiguri

30 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.2B

3.6B

Deschiderea anterioară

26.71

Închiderea anterioară

28.6

Sentimentul știrilor

By Acuity

34%

66%

108 / 371 Clasament în Healthcare

Apellis Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 oct. 2025, 20:49 UTC

Câștiguri

Correction to Thermo Fisher Article on Oct. 22

23 oct. 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct. 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct. 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 oct. 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct. 2025, 22:49 UTC

Achiziții, Fuziuni, Preluări

How Trump Sparked a New Era of State Capitalism -2-

23 oct. 2025, 22:49 UTC

Achiziții, Fuziuni, Preluări

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct. 2025, 22:17 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct. 2025, 21:41 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct. 2025, 21:05 UTC

Câștiguri

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 oct. 2025, 20:35 UTC

Câștiguri

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct. 2025, 20:28 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct. 2025, 20:15 UTC

Market Talk
Câștiguri

Global Commodities Roundup: Market Talk

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q Adj EPS $1.71

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q Sales $5.52B

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q EPS $1.67

23 oct. 2025, 20:09 UTC

Câștiguri

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct. 2025, 20:07 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

23 oct. 2025, 20:07 UTC

Market Talk
Câștiguri

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct. 2025, 20:07 UTC

Câștiguri

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct. 2025, 20:05 UTC

Câștiguri

Intel 3Q Gross Margin 38.2% >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct. 2025, 20:04 UTC

Câștiguri

Intel: 4Q Guidance Excludes Altera >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel Sees 4Q Adj EPS 8c >INTC

Comparație

Modificare preț

Apellis Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

28.14% sus

Prognoză pe 12 luni

Medie 36.06 USD  28.14%

Maxim 60 USD

Minim 18 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruApellis Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

10

Cumpărare

6

Păstrare

1

Vânzare

Sentiment

By Acuity

108 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
help-icon Live chat